Green Bay school district faces at least $10M budget deficit in 2026-27. What comes next?
Three years after announcing a $36 million budget deficit, the Green Bay school district is still facing a fiscal cliff.
Despite school consolidations and other cost-cutting moves, the district is now facing at least a $10 million to $12 million budget shortfall in 2026-27, superintendent Vicki Bayer told the board at its Monday meeting.
As it prepares, Green Bay is also waiting on a state budget that administrators worry may not be set by the start of the school year. Political back-and-forth has meant it's not clear whether districts will be seeing Gov. Tony Evers' proposed $325 education funding increase per student, and Bayer expressed concern that lawmakers wouldn't be able to agree on a budget in time for the district to make difficult financial decisions.
"The word escapes me to address the situation we've been put in by the way schools are funded in the state of Wisconsin,' Bayer said Monday night.
Green Bay is staring down the barrel of another multimillion-dollar deficit within the next two years. It's not the only one — districts across Wisconsin are facing financial struggles as inflation squeezes set district revenue limits.
'Our goal is, when we're reducing our budget, to have the least amount of negative impact on our children. At some point, the state of Wisconsin has to realize we can't keep cutting without hurting our children,' Bayer said.
It currently projects a $10 million to $12 million deficit, although that's including Evers' proposed $325 per pupil, despite it being tied up in courts — without it, that projection goes up by around $6 million.
The district's been forecasting budget deficits since June 2022, when it initially projected a $36 million deficit for the 2024-25 school year. By May 2024, it had closed that gap by downsizing staff, reducing costs and consolidating schools, among other cuts. It also relied on federal pandemic relief funding, or ESSER funds, that expired last September to bridge the gap.
But the core issues driving the original deficit still exist. Bayer and Angie Roble, the district's chief financial officer, pointed to the district's low revenue ceiling, meaning it can only bring in so much per pupil, and low special education funding reimbursement rates, which mean the district has to reassign general funds to meet students' needs.
In addition, the district's $16.5 million operating referendum ends the same year, 2026-27. It'll likely have to turn to voters for additional operating dollars.
With all that in mind, the district is planning with no idea what the state budget will look like. Administrators need to know how much they'll be receiving from the state before they can start deciding how much they'll need to ask for in a new operating referendum.
Right now, Green Bay is considering a variety of options to address the projected deficit. Most would affect teacher pay and benefits: on the table are things like putting a hold on base wage negotiations until the state budget is passed, freezing annual salary 'step' increases for a year or replacing Green Bay's income protection plan, the district-sponsored short-term disability plan, for a voluntary employee-paid version.
The district is also considering reducing or closing Katherine Johnson Academy of Enriched Virtual Learning, its online-only option. When the board was initially considering school consolidations in November 2023, it debated closing KJ Academy.
Online enrollment numbers show the school had 66 students as of September; however, parents, teachers and board members emphasized the transitional nature of the school, meaning students come and go. One teacher stated enrollment at one point this year included 119 unique students.
If the district doesn't ultimately receive the extra $325 per pupil, those changes could quickly get more drastic.
'Our recommendation at that point would probably be taking a look at class sizes and layoffs,' Bayer said.
Green Bay isn't the only Wisconsin district facing financial difficulties, but it's in a particularly difficult situation because of how state school funding works out.
In the 1990s, the state put a ceiling on how much funding school districts could bring in per pupil, and districts who spent more conservatively at the time, like Green Bay, were stuck at that low level. That cap initially increased slightly with inflation each year, but that changed in 2009.
'School districts never got caught up,' Bayer said. 'We've never received the funding to make up for the stop in that inflationary increase.'
Districts have also had to deal with factors like declining enrollment, which led to Green Bay's school consolidations.
This article originally appeared on Green Bay Press-Gazette: Green Bay school district faces at least $10M budget deficit in 2026-27

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
How to Organize a Health Technology Business with Focus on 10+ Organizational Archetypes
Discover the evolving organizational structures of digital health businesses in the Pharma and MedTech sectors. This report analyzes 11 HealthTech archetypes over 15 years, offering insights on performance across key KPIs, future trends, and strategic recommendations. Featured companies include Bayer, Roche, and more. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "How to Organize a HealthTech Business?" report has been added to offering. This report sheds light on how to organize digital health businesses, especially at large Pharma and MedTech companies. By looking at how other companies have been managing their HealthTech businesses over the last 15 years, 11 different HealthTech organizational archetypes are being detailed out in the report, including their objectives, responsibilities, team sizes, target partner company stages, governance, value propositions for their partners, business impact evaluations across 4 KPIs and real-life examples from companies who had deployed these structures. Performance of the 11 archetypes are then evaluated and compared across the four main KPIs which are based on finding partners, launching solutions, driving usages & cultural change support. Based on the evaluation of the success and impact of these archetypes, the report presents a benchmarking table of HealthTech business organizations today. With a deep-dive into the evolving trends in HealthTech business organizations responding to the changing market conditions across three main market phases, 5 trend points for future and relevant recommendations are provided on what needs to be done to stay competitive and move forward in growing digital health market. Questions the report answers: What are the archetypes to organize HealthTech businesses at Pharma and MedTech companies? What are the different objectives and responsibilities of each organizational archetype? How are the archetypes governed at larger corporates? How does each organizational archetype perform? Which Pharma and MedTech apply which archetype to manage their HealthTech business today? How did the archetypes evolve to adept the market conditions today? What does the market require for organization of HealthTech businesses in 3-5 years? Interested parties can benefit from this report in the following ways: Consultants: gain insights into different organizational structures within the HealthTech industry, and enhance the ability to advise clients on optimal structuring and strategic alignment for digital health initiatives Strategy heads: understand how leading organizations structure their HealthTech initiatives, which can inform strategic planning and decision-making processes Business unit heads: understand how to integrate digital health solutions into the units effectively, determine the most suitable structure for the unit, and align with overall corporate objectives Digital health unit heads: benchmark your organizational structure against others, know what is needed in terms organizational structure to stay competitive in the growing digital health market, and optimize your organizational structure to foster innovation and integration with business units In this report, the following companies are mentioned: Bayer Roche Biogen Sanofi Siemens Healtineers GE Healthcare Janssen (J&J) MSD Merck KGaA Novartis Becton Dickenson and Company *30 min report consultation with a research analyst available with the purchase of an enterprise license Key Topics Covered: Archetype-1: Central Teams Archetype-2: De-Central Teams Archetype-3: Carve-Outs Archetype-4: Innovation Hubs Archetype-5: Incubators Archetype-6: Accelerators Archetype-7: Collaborative Accelerators Archetype-8: People Accelerators Archetype-9: Marketplace Organizations Archetype-10: Venture Funds Archetype-11: Outsourcing The Influence of Market Maturity on the Development of HealthTech Organizational Forms Building Successful HealthTech Teams for the Next 3-5 Years For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
MustGrow Biologics Corp (MGROF) Q1 2025 Earnings Call Highlights: A Promising Start with ...
Sales Revenue: $3.8 million for Q1 2025. Gross Profit: Approximately $540,000. Gross Margin: 14.3%. Cash Position: $2 million. NexusBioAg Sales: Historical sales between $15 million to $20 million, with expectations to maintain this range. Shares Outstanding: 52 million shares, 59 million fully diluted. Warning! GuruFocus has detected 5 Warning Signs with MGROF. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MustGrow Biologics Corp (MGROF) reported $3.8 million in sales revenue for Q1 2025, marking a significant milestone as their initial sales numbers. The company successfully integrated NexusBioAg, a sales and distribution division, which contributed to the Q1 sales. MustGrow Biologics Corp (MGROF) has a strong partnership with Bayer, which includes a commercial agreement in Europe, Middle East, and Africa, with potential for milestone and royalty payments. The company holds 112 patents, showcasing a robust intellectual property portfolio, and is actively working on new IP generation. MustGrow Biologics Corp (MGROF) is focusing on a high-growth, asset-light model, with a tight capital structure and plans to drive revenue and margin growth. The gross margin for Q1 2025 was 14.3%, which was negatively affected by foreign exchange fluctuations and tariffs. Sales for TerraSante have not yet ramped up significantly, with expectations for more meaningful sales in late 2025 or early 2026. The company faces challenges with the registration process for TerraMG, with potential registration not expected until 2026. MustGrow Biologics Corp (MGROF) is assessing the need for additional working capital to drive revenue growth, indicating potential financial constraints. The agricultural market's seasonality and cyclicality present challenges in sales predictability and revenue generation. Q: Sales so far were all from Canada, right? Were any of them from TerraSante? A: Yes, Q1 sales were all in Canada, specifically through NexusBioAg. TerraSante sales in the US are expected to ramp up in the second half of this year. Q: How have tariffs affected sales, specifically for TerraSante? A: Our products were not directly affected by tariffs, but there were indirect effects such as a weaker Canadian dollar, which negatively impacted margins. Q: Are you able to provide any sort of a forecast for TerraSante? A: No, we do not provide forecasts at this time. Q: Is the regenerative or natural input market for agriculture growing faster than traditional inputs? A: Yes, the regenerative agriculture market is growing at a significant double-digit CAGR compared to the single-digit growth of the synthetic market. Q: When do you expect to see positive free cash flow? A: Our goal is to achieve positive cash flows next year, potentially into 2027, by driving revenues and margins. Q: Do you need more working capital for inventory to drive your revenues? A: Yes, we are assessing access to capital, including non-dilutive options, to support revenue and margin growth. Q: Are there any updates on the registration process for TerraMG? A: In North America, we are progressing with registrations and hope to have them by 2026. Bayer is also working on registrations in Europe, the Middle East, and Africa. Q: Does NexusBioAg only focus on Western Canada, or do they have a presence in Eastern Canada as well? A: NexusBioAg has coverage across Canada, with significant operations in both Western and Eastern Canada. Q: Are there any more impactful products in the pipeline to run through Nexus? A: Yes, there are many products in the pipeline, and we are leveraging Nexus's market access and relationships to introduce them. Q: Is there a push to open up or get approval in more US states? A: Currently, we are focusing on accelerating sales in California, Washington, Oregon, and Idaho, with potential expansion to other states being assessed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
2 days ago
- Yahoo
MustGrow Biologics Corp (MGROF) Q1 2025 Earnings Call Highlights: A Promising Start with ...
Sales Revenue: $3.8 million for Q1 2025. Gross Profit: Approximately $540,000. Gross Margin: 14.3%. Cash Position: $2 million. NexusBioAg Sales: Historical sales between $15 million to $20 million, with expectations to maintain this range. Shares Outstanding: 52 million shares, 59 million fully diluted. Warning! GuruFocus has detected 5 Warning Signs with MGROF. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MustGrow Biologics Corp (MGROF) reported $3.8 million in sales revenue for Q1 2025, marking a significant milestone as their initial sales numbers. The company successfully integrated NexusBioAg, a sales and distribution division, which contributed to the Q1 sales. MustGrow Biologics Corp (MGROF) has a strong partnership with Bayer, which includes a commercial agreement in Europe, Middle East, and Africa, with potential for milestone and royalty payments. The company holds 112 patents, showcasing a robust intellectual property portfolio, and is actively working on new IP generation. MustGrow Biologics Corp (MGROF) is focusing on a high-growth, asset-light model, with a tight capital structure and plans to drive revenue and margin growth. The gross margin for Q1 2025 was 14.3%, which was negatively affected by foreign exchange fluctuations and tariffs. Sales for TerraSante have not yet ramped up significantly, with expectations for more meaningful sales in late 2025 or early 2026. The company faces challenges with the registration process for TerraMG, with potential registration not expected until 2026. MustGrow Biologics Corp (MGROF) is assessing the need for additional working capital to drive revenue growth, indicating potential financial constraints. The agricultural market's seasonality and cyclicality present challenges in sales predictability and revenue generation. Q: Sales so far were all from Canada, right? Were any of them from TerraSante? A: Yes, Q1 sales were all in Canada, specifically through NexusBioAg. TerraSante sales in the US are expected to ramp up in the second half of this year. Q: How have tariffs affected sales, specifically for TerraSante? A: Our products were not directly affected by tariffs, but there were indirect effects such as a weaker Canadian dollar, which negatively impacted margins. Q: Are you able to provide any sort of a forecast for TerraSante? A: No, we do not provide forecasts at this time. Q: Is the regenerative or natural input market for agriculture growing faster than traditional inputs? A: Yes, the regenerative agriculture market is growing at a significant double-digit CAGR compared to the single-digit growth of the synthetic market. Q: When do you expect to see positive free cash flow? A: Our goal is to achieve positive cash flows next year, potentially into 2027, by driving revenues and margins. Q: Do you need more working capital for inventory to drive your revenues? A: Yes, we are assessing access to capital, including non-dilutive options, to support revenue and margin growth. Q: Are there any updates on the registration process for TerraMG? A: In North America, we are progressing with registrations and hope to have them by 2026. Bayer is also working on registrations in Europe, the Middle East, and Africa. Q: Does NexusBioAg only focus on Western Canada, or do they have a presence in Eastern Canada as well? A: NexusBioAg has coverage across Canada, with significant operations in both Western and Eastern Canada. Q: Are there any more impactful products in the pipeline to run through Nexus? A: Yes, there are many products in the pipeline, and we are leveraging Nexus's market access and relationships to introduce them. Q: Is there a push to open up or get approval in more US states? A: Currently, we are focusing on accelerating sales in California, Washington, Oregon, and Idaho, with potential expansion to other states being assessed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data